Tyra Biosciences has launched the SURF302 study of an investigational oral therapy for non-muscle invasive bladder cancer. The trial will test safety and effica

Tyra Biosciences has launched the SURF302 study of an investigational oral therapy for non-muscle invasive bladder cancer. The trial will test safety and efficacy as the company seeks to reduce treatment burden and challenge current care models.